FDA’s Cell Therapy Panel Revisits a Once-Rejected DMD Drug

FDA's Cellular, Tissue, and Gene Therapies Advisory Committee meets 29 July 2026 on a product it has already turned down once. The panel will discuss and make recommendations on Biologics License Application (BLA) 125842, from Capricor, Inc., for deramiocel — a cell therapy proposed for cardiomyopathy in Duchenne muscular dystrophy (DMD) — a year after FDA issued a Complete Response Letter citing, among other things, unresolved manufacturing questions. FDA amended the meeting notice on 24 July, days before the docket closes and the committee convenes.

The second time at the podium

Deramiocel is not a new name to this committee's docket. Capricor's BLA was granted Priority Review in March 2025, supported by the Phase 2 HOPE-2 trial, its open-label extension, and comparisons against FDA-funded natural-history data. FDA's Complete Response Letter, posted that July, said the application did not meet the statutory standard for substantial evidence of effectiveness and separately flagged outstanding items in the chemistry, manufacturing, and controls (CMC) section — the part of a filing that documents how consistently a product can actually be made. Capricor said at the time it believed it had already addressed the CMC points in prior communications with the agency; the letter arrived anyway.

The company's answer was more data, not just a rebuttal. Capricor resubmitted the BLA with topline results from HOPE-3, a randomized, multicenter, placebo-controlled, double-blind Phase 3 trial, which the company has said reached statistical significance on its primary endpoint (PUL v2.0, a measure of upper-limb function), on the key secondary cardiac endpoint (left ventricular ejection fraction), and on its other Type I error-controlled secondary endpoints. FDA treated the filing as a Class 2 resubmission, restarted its review clock, and in March 2026 lifted the CRL, setting the current PDUFA target action date of 22 August 2026 — three weeks after this committee meets.

What the amendment actually changed

The meeting itself was set in a notice FDA published 29 June 2026, at pages 39101–39103 of the Federal Register, establishing Docket FDA-2026-N-6771 for public comment. On 24 July, five days before the meeting, FDA published an amendment correcting the DATES, ADDRESSES, and procedural sections of that notice. The visible result: the committee's published hours are now 9:30 a.m. to 4:50 p.m. Eastern — a longer session than the original notice set, on the same 29 July date.

• 28 July 2026, 11:59 p.m. ET — Docket FDA-2026-N-6771 closes to electronic and written comments.
• 29 July 2026, 9:30 a.m.–4:50 p.m. ET — the committee meets in open session, online, to discuss and make recommendations on BLA 125842.
• 22 August 2026 — the PDUFA target action date by which FDA is due to decide on the resubmitted BLA.

Why a CMC-driven rejection is the harder kind

A Complete Response Letter built on efficacy data invites more trials; one that also flags CMC gives a sponsor a narrower, more mechanical problem to solve — and cell and gene therapies are exactly the modality where that problem is hardest, because the product and the process that makes it are much harder to separate than they are for a small-molecule drug. It is the same tension FDA's own chemistry, manufacturing, and controls strategy document, published four days before this amendment, is aimed at: sponsors on accelerated timelines reaching a pivotal filing with a clinical package in hand and a manufacturing package still catching up. Whether the committee's questions on 29 July dwell on the clinical data alone, or reopen the manufacturing record, will be visible in the transcript FDA posts afterward.

The mechanism is the same one that sent FDA's other cell and gene therapy panel to a public docket three weeks ago, over a different product entirely: the agency's Cellular, Tissue, and Gene Therapies Advisory Committee review of Replimune's melanoma biologic. Neither meeting's vote binds FDA. Both put a sponsor's evidence, and the questions a reviewer is asking about it, into the public record before the agency has to decide.